Allarity Therapeutics, Inc. — Form 8-K
Filed October 30, 2026 · analyzed by the 8-K Agent
8-K
▼ Likely negative
significance 72/100
What the filing says
Allarity Therapeutics filed an 8-K on October 30, 2026 reporting termination of a material definitive agreement effective October 28, 2026. The filing does not disclose the counterparty name, financial terms, dollar amounts, or business rationale for the termination.
Why this rating
Material agreement termination is inherently significant for a $14.7M company; lack of disclosure prevents full assessment but suggests material impact to operations or financing.
Extracted items
- 1.02 agreement termination
Price action (we called it negative)
before filing · preread $0.89 | at our read pending | +10 min pending | +30 min pending | +1 hr pending | +4 hrs pending |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from October 30, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.